Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
Addiction Biology|May 16, 2015
The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteersZiva D Cooper, Kirk W Johnson, Martina Pavlicova, et al.
British Journal of Pharmacology|March 21, 2017
CGRP receptor activity in mice with global expression of human receptor activity modifying protein 1Keegan J Bohn, Baolin Li, Xiaofang Huang, et al.
Journal of Medicinal Chemistry|August 20, 2004
DNA binding ligands with improved in vitro and in vivo potency against drug-resistant Staphylococcus aureusWenhao Hu, Roland W Bürli, Jacob A Kaizerman, et al.
Neuron Glia Biology|January 8, 2008
The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic painAnnemarie Ledeboer, Tongyao Liu, Jennifer A Shumilla, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitorSandhya Ramanathan-Girish, Juliet McColm, John M Clements, et al.
Clinical Pharmacology and Therapeutics|August 10, 2023
TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde-Evoked Dermal Blood Flow Increase: Translational Proof of PharmacologyDorien Bamps, Anthony James Blockeel, Erwin Dreesen, et al.
Brain, Behavior, and Immunity|December 19, 2006
Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in ratsAnnemarie Ledeboer, Brian M Jekich, Evan M Sloane, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
DNA binding ligands with in vivo efficacy in murine models of bacterial infection: optimization of internal aromatic amino acidsRoland W Bürli, Jacob A Kaizerman, Jian-Xin Duan, et al.
Experimental Neurology|July 19, 2005
AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parametersLaura M Sanftner, Jurg M Sommer, Brian M Suzuki, et al.
Cephalalgia : an International Journal of Headache|August 21, 2025
Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraineMichael P Johnson, Judith Krikke-Workel, Chetan N Patel, et al.
Pageof 7